Predictive Model of Gemtuzumab Ozogamicin Response in Childhood Acute Myeloid Leukemia on Event-Free Survival: Data Analysis Based on Trial AAML0531
<b>Purpose:</b> We aimed to develop a simple nomogram and online calculator that can identify the optimal subpopulation of pediatric acute myeloid leukemia (AML) patients who would benefit most from gemtuzumab ozogamicin (GO) therapy. <b>Methods:</b> Within the framework of the phase Ⅲ AAML0531 rand...
Enregistré dans:
| Auteurs principaux: | , , , |
|---|---|
| Format: | Artigo |
| Langue: | Inglês |
| Publié: |
MDPI AG
2025-03-01
|
| Collection: | Bioengineering |
| Sujets: | |
| Accès en ligne: | https://www.mdpi.com/2306-5354/12/3/297 |
| Tags: |
Pas de tags, Soyez le premier à ajouter un tag!
|